ACADIA PHARMACEUTICALS INC (ACAD)
NASDAQ • Healthcare
$30.18
+$1.16 (+4.0%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About ACADIA PHARMACEUTICALS INC
Name
ACADIA PHARMACEUTICALS INC
CEO
Catherine E. Owen Adams
Website
Industry
Healthcare
Year Founded
1993
Employees
797
ACADIA Pharmaceuticals Inc. develops and commercializes small-molecule therapies for central nervous system disorders and operates in biotechnology within the healthcare sector. The NASDAQ-listed company trades as ACAD, and its only marketed product, NUPLAZID, helped generate $1.1 billion of revenue in FY2025.
Fundamentals & Financials
Revenue (TTM)
$1.1B
Net Income (TTM)
$380.4M
EPS (TTM)
$2.25
ROA (TTM)
21.83%
Current Ratio
3.39
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$30.18$29.05 - $30.25
52 Week RangeAvg. Volume$19.69 - $30.251.7M
Market CapP/E Ratio$5.2B13.4
Peers & Related Assets
PRAXPRAXIS PRECISION MEDICINES INC
$369.84-1.7%
IMVTIMMUNOVANT INC
$44.3+1.4%
CRNXCRINETICS PHARMACEUTICALS INC
$84.72-0.0%
MIRMMIRUM PHARMACEUTICALS INC
$100.87+1.0%
LGNDLIGAND PHARMACEUTICALS INC
$287.59-1.4%
DYNDYNE THERAPEUTICS INC
$26-0.6%
VKTXVIKING THERAPEUTICS INC
$33.37-0.8%
ADMAADMA BIOLOGICS INC
$9.54+2.1%
BLTEBelite Bio, Inc
SLNOSOLENO THERAPEUTICS INC